Publicaciones en colaboración con investigadores/as de Beckman Research Institute (5)

2023

  1. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma

    Oncologist, Vol. 28, Núm. 1, pp. 59-71

2022

  1. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

    European Urology, Vol. 82, Núm. 3, pp. 283-292

2021

  1. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Journal of Clinical Oncology, Vol. 39, Núm. 33, pp. 3725-3736

2018

  1. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non–clear cell renal cell carcinoma

    Cancer Immunology Research, Vol. 6, Núm. 7, pp. 758-765

2017

  1. Borealis-1: A randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

    Annals of Oncology, Vol. 28, Núm. 10, pp. 2481-2488